China Biotech

Business

Perspective Therapeutics Surges on Promising Cancer Trial Data, But Valuation Gap Raises Questions

Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.

Feb 2, 2026

US

West Virginia Sees Major Immigration Enforcement Operation, Over 650 Arrested in Statewide Sweep

A coordinated two-week operation between ICE and multiple West Virginia law enforcement agencies has resulted in the arrest of more than 650 individuals for immigration violations, including some with criminal histories.

Feb 2, 2026

Business

Euro's Surge Casts Shadow Over ECB Policy Meeting

The European Central Bank convenes this week with a resurgent euro presenting a fresh dilemma, threatening to dampen inflation and undermine the export engine of the eurozone's largest economies just as recovery gains momentum.

Feb 2, 2026

Business

Glaukos Gains FDA Label Expansion for iDose TR, But Valuation Questions Loom

Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.

Feb 2, 2026

Business

Exelixis Submits Zanzalintinib to FDA, Bolstering Oncology Pipeline with Key Colorectal Cancer Candidate

Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.

Feb 2, 2026

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Feb 2, 2026

Business

Glaukos Gains FDA Nod for Repeat iDose TR Implant, Bolstering Its Long-Term Glaucoma Platform Strategy

The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.

Feb 2, 2026

Business

BeOne Medicines: A Valuation Check Amidst Volatile Trading and Long-Term Promise

BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.

Feb 2, 2026

Business

Starbucks' Grip on U.S. Coffee Drinkers Loosens Amid Fierce Competition

While America's coffee consumption hits multi-decade highs, Starbucks' market share is eroding. The pioneer now faces a crowded battlefield of value-focused rivals, drive-thru specialists, and international entrants, forcing a strategic rethink of its iconic 'third place' model.

Jan 31, 2026

Business

Sarepta's Gene Therapy Shows Sustained Slowing of DMD Progression in Landmark Three-Year Data

New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.

Jan 31, 2026

Business

Danaher Forges Strategic Alliance with Automata, Accelerating AI-Powered Laboratory Automation

Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.

Jan 31, 2026

Business

Apple vs. Meta: A Tale of Two Tech Titans in the Magnificent Seven

As earnings season unfolds, Apple and Meta Platforms both posted impressive results, but their paths diverge sharply. Apple's growth reaccelerates on iPhone strength, while Meta's robust outlook is shadowed by soaring AI investments. The debate over which stock offers the better value is heating up.

Jan 31, 2026

Business

Day One Biopharmaceuticals: Surging Momentum Raises Valuation Questions Amid High-Stakes Pipeline

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.

Jan 31, 2026

Business

AstraZeneca's Valuation Puzzle: Strong Pipeline and Steady Gains Mask Undervalued Opportunity?

Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.

Jan 31, 2026

Business

Chevron Eyes Major Expansion of Venezuelan Oil Imports Following U.S. License Shift

Chevron CEO Mike Wirth signals the energy giant could significantly ramp up processing of Venezuelan crude at its U.S. refineries, following a pivotal Treasury Department license that eases trade restrictions with Caracas.

Jan 31, 2026

Business

Weyerhaeuser Navigates Brutal Lumber Markets, Bets on Land and Climate for Growth

Despite posting a quarterly loss in its core wood products unit amid 'extremely challenging' markets, Weyerhaeuser closed 2025 with strategic pivots. The forestry giant is doubling down on its land management and nascent 'Climate Solutions' business, while managing a disciplined capital return to shareholders.

Jan 31, 2026

Business

Tencent's Stock Cools Off: Is the Tech Giant Now a Value Play?

After a stellar 52% annual gain, Tencent Holdings' (SEHK:700) share price momentum has stalled in the near term. With the stock trading at HK$606, analysts debate whether this presents a buying opportunity or reflects deeper market caution.

Jan 31, 2026

Business

CK Hutchison's Stock Surge: Momentum Play or Overheated Valuation?

CK Hutchison Holdings (SEHK:1) has seen its share price rally sharply, with recent one- and three-month returns significantly outpacing its year-to-date performance. This surge prompts a closer look at whether the conglomerate's current valuation represents a genuine opportunity or has run ahead of fundamentals.

Jan 31, 2026

Business

Minerals Technologies Navigates a Challenging 2025, Bets on Strategic Investments for 2026 Growth

Facing softer demand and tariff volatility, Minerals Technologies (MTX) reported steady 2025 sales of $2.1B but saw margins contract. Leadership emphasized cost discipline and safety while detailing a series of expansion projects poised to drive a meaningful rebound in the coming year.

Jan 31, 2026

Business

Novo Nordisk's Oral Weight-Loss Drug Sees Blockbuster Debut, Fueling Investor Optimism for Stock Rebound

Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.

Jan 30, 2026